At present there is no established adjuvant treatment for GIST, but several ongoing studies have explored imatinib in the adjuvant setting. One study randomized patients to receive imatinib or ...

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...

Hoth Therapeutics Inc. has released preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST).

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...

Further, HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment. "By directly targeting the underlying genetic drivers of GIST, HT-KIT has the potential to overcome ...

Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...

Based on the insights into the mechanisms underlying sensitivity to TKIs, it is very likely that the number of treatment options for patients with GIST will expand. Before such novel treatment ...